Estramustine: profile and news

Positive Findings From Clinical Studies of QUADRAMET(R) in ... Feb 27, 2006
...with castration-refractory bone metastases from prostate cancer with response or stabilization after induction docetaxel-estramustine: Preliminary results.". ... - International News Service,

Positive Findings from Clinical Studies of Quadramet in Prostate ... Feb 27, 2006
With Castration-Refractory Bone Metastases From Prostate Cancer With Response or Stabilization After Induction Docetaxel-Estramustine: Preliminary Results. ... - DG News

Positive Findings from Clinical Studies of QUADRAMET in Prostate ... Feb 27, 2006
...in patients with progressive hormone refractory prostate cancer with response or stabilization after induction therapy with docetaxel plus estramustine. ... - PharmaLive.com (press release),

Other information

Indication
For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate

Pharmacology
Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nornitrogen mustard. The precise mechanism of action of estramustine is unknown. Unlike other alkylating agents, estramustine does not directly damage DNA.

Mechanism Of Action
The precise mechanism of action of estramustine is unknown.

Drug Category
Antineoplastic Agents; Antineoplastic Agents; Radiation-Protective Agents; ATC:L01XX11

Brand Names/Synonyms
Emcyt; Estracyt; Estramustin Sodium Phosphate; Estramustina [Inn-Spanish]; Estramustine; Estramustine Sodium Phosphate; Estramustine [Usan:Ban:Inn]; Estramustinum [Inn-Latin]; Leo 275

Dosage Forms
CAPSULE

Absorption
Not Available

Interactions
Interactions for Estramustine:

Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.

Chemical IUPAC Name
(17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl)bis(2-chloroethyl)aminomethanoate

Chemical Formula
C23H31Cl2NO3

Half Life
20 hours

Drug Type
Approved Drug

# Accession No
APRD00625

CAS Registry Number
2998-57-4